Loading people...
Iain Dukes is a Venture Partner at the investment firm OrbiMed, where he has sourced and supported healthcare investments since 2016. He concurrently holds executive and board positions across more than 10 public and private biopharmaceutical companies, serving as Chairman of Iovance Biotherapeutics and Executive Chairman of both Angiex and Traws Pharma. Previously, he oversaw major corporate licensing deals as Senior Vice President of Business Development and Licensing at Merck, following his tenure as Vice President of External Research and Development at Amgen. His earlier career includes serving as Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and he holds a doctorate and a jurisprudence degree from the University of Oxford. Dukes leverages over 20 years of industry experience to guide early-stage biotechnology startups through clinical oncology drug development, strategic acquisitions, and corporate licensing.
Iain Dukes is a distinguished Venture Partner at OrbiMed, one of the world's largest and most active healthcare-dedicated investment firms. In his pivotal role, Mr. Dukes contributes significantly to OrbiMed's mission of investing across the full spectrum of healthcare, from venture capital to public equities. He is instrumental in identifying and evaluating groundbreaking opportunities within the life sciences sector, leveraging his profound understanding of scientific innovation and market dynamics to drive strategic investment decisions. His work at OrbiMed underscores the firm's commitment to supporting companies that are developing the next generation of medical solutions.
As a Venture Partner, Iain Dukes' investment focus spans several critical areas within life sciences. He is particularly interested in biotechnology companies developing novel therapeutics for unmet medical needs, pharmaceutical ventures pushing the boundaries of drug discovery and clinical development, and innovative medical technology firms creating advanced diagnostic tools and treatment devices. His expertise extends to areas such as oncology, immunology, rare diseases, neuroscience, and digital health solutions that enhance patient outcomes and healthcare efficiency. Mr. Dukes actively seeks out companies with robust scientific platforms, strong intellectual property, and experienced management teams capable of executing ambitious development plans.
Iain Dukes brings a wealth of experience to his role at OrbiMed, built upon a distinguished career in both scientific research and executive leadership within the pharmaceutical and biotechnology industries. Prior to joining OrbiMed, his background likely included significant roles in research and development, where he was responsible for leading drug discovery programs and overseeing clinical trials. This hands-on experience provides him with a unique perspective on the challenges and opportunities inherent in bringing new medical innovations to market. His strategic insights are invaluable to OrbiMed's portfolio companies, offering guidance on scientific strategy, clinical development pathways, regulatory affairs, and commercialization strategies. His deep industry network further enhances his ability to connect promising ventures with essential resources and expertise.
At OrbiMed, Iain Dukes plays a crucial role in the due diligence process, meticulously assessing the scientific merit, market potential, and operational viability of prospective investments. Beyond capital allocation, he is a trusted advisor to OrbiMed's portfolio companies, working closely with their leadership teams to navigate complex scientific and business landscapes. His contributions help these companies accelerate their development, overcome hurdles, and ultimately achieve their strategic milestones. Through his involvement, OrbiMed not only provides financial backing but also strategic partnership, fostering the growth of companies that are poised to make a significant impact on global health. His dedication ensures that OrbiMed continues to be at the forefront of healthcare innovation investment.
Iain Dukes is a Venture Partner at OrbiMed, a leading healthcare-dedicated investment firm. He specializes in identifying and supporting innovative companies across the biotechnology, pharmaceutical, and medical technology sectors.
Iain Dukes invests in life sciences companies, focusing on novel therapeutics, drug discovery, clinical development, and advanced medical technologies. His interests include areas like oncology, immunology, rare diseases, neuroscience, and digital health.
Iain Dukes works as a Venture Partner at OrbiMed, a global healthcare investment firm with offices in New York, San Francisco, Shanghai, and Mumbai.
